Scholars Central

Conference abstractPublished 26 Oct 2015

Evolving biosimilars regulatory landscape - US and EU

Authors: Kamali Chance

Quintiles, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The regulatory landscape for the development of biosimilars in the US and EU is dynamic as many of the guidances issued by European Medicines Agency (EMA) have undergone revisions and in 2015, the FDA issued number of revised guidelines for Quality and Scientific Considerations as well as updated Questions and Answers documents that lend much clarity as to FDA expectations.The thinking of the regulators both in the EU and US has evolved over the years and there is a great deal of convergence. This session is designed to provide current status of biosimilar guidelines in the US and EU. The focus will be to identify major updates in order to help sponsors navigate through the complex requirements for the regulatory approval of biosimilars in the US and EU.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels